Vietnam is accelerating the adoption of point-of-care (POC) molecular diagnostics as healthcare providers seek faster, more accurate disease detection in hospitals, clinics and community healthcare settings. By bringing laboratory-quality molecular testing directly to the patient, these technologies are helping clinicians make quicker treatment decisions while expanding access to advanced diagnostics beyond central laboratories.
According to IMARC Group, Vietnam's Point-of-Care Molecular Diagnostics market reached US$43.9 million in 2025 and is projected to grow to US$81.0 million by 2034.
Point-of-care molecular diagnostics combine advanced molecular biology techniques with portable testing platforms capable of detecting pathogens and genetic markers within minutes rather than days. Modern systems can deliver laboratory-quality results directly in emergency departments, outpatient clinics, intensive care units, community health centres and even remote healthcare facilities.
The market includes a wide range of technologies, including:
- Portable PCR systems
- Isothermal nucleic acid amplification (INAAT) platforms
- Microfluidic lab-on-a-chip devices
- Rapid molecular infectious disease tests
- Oncology diagnostics
- Prenatal molecular testing
- DNA sequencing-based point-of-care platforms
- Integrated software and cloud-based diagnostic services
Several structural trends are supporting market growth across Vietnam:
- Expansion of decentralised healthcare services.
- Increasing demand for rapid infectious disease diagnosis.
- Greater investment in provincial hospital infrastructure.
- Rising adoption of molecular testing in oncology and personalised medicine.
- Government programmes strengthening disease surveillance.
- Integration of artificial intelligence into diagnostic workflows.
- Growing need for faster clinical decision-making in emergency and critical care.
One of the strongest growth drivers is the continued expansion of rapid molecular testing for infectious diseases. IMARC Group notes that portable PCR platforms, isothermal amplification technologies and microfluidic systems are increasingly being deployed throughout Vietnam, enabling accurate molecular testing outside traditional laboratory environments. The report highlights that advanced molecular testing platforms have already been deployed at more than 200 healthcare locations nationwide, significantly reducing diagnostic turnaround times for diseases such as tuberculosis.
The wider point-of-care diagnostics sector is also expanding rapidly. According to IMARC Group, Vietnam's overall Point-of-Care Diagnostics market reached US$230.5 million in 2025 and is forecast to grow to US$465.4 million by 2034. Molecular diagnostics is one of the fastest-growing technology platforms within this broader market as healthcare providers increasingly prioritise rapid, high-accuracy testing.
Vietnam's broader molecular diagnostics industry continues to provide a strong foundation for future growth. IMARC Group estimates the country's Molecular Diagnostics market reached US$108.5 million in 2025 and is expected to grow to US$175.6 million by 2034, supported by increasing demand for infectious disease testing, oncology diagnostics, genetic testing and personalised medicine.
Technology continues to reshape the sector. Modern point-of-care molecular systems increasingly combine artificial intelligence, cloud connectivity and automated sample preparation with highly sensitive nucleic acid amplification technologies. AI-assisted interpretation helps clinicians analyse results more rapidly, while compact "sample-to-answer" platforms reduce operator training requirements and make advanced molecular testing accessible in resource-limited settings. Emerging microfluidic and lab-on-a-chip technologies are further reducing testing times while improving portability and affordability.
Leading manufacturers including Cepheid (Danaher), Abbott, Roche Diagnostics, bioMérieux, Qiagen, Thermo Fisher Scientific, Hologic, Becton Dickinson (BD), QuidelOrtho and Siemens Healthineers continue to expand their portfolios of rapid molecular diagnostic platforms, supporting applications ranging from infectious disease detection to oncology and genetic testing.
As Vietnam continues to modernise its healthcare system and strengthen diagnostic capacity nationwide, point-of-care molecular diagnostics are expected to play an increasingly important role in delivering faster, more accessible and more personalised healthcare. For manufacturers of molecular diagnostic instruments, assays, microfluidic technologies, AI-enabled diagnostic software and laboratory automation solutions, Vietnam represents one of Southeast Asia's most promising long-term growth opportunities.